🔎 Trials Near Me

መነሻ › ክሮኒክ ሊምፎሳይቲክ ሉኬሚያ › Ohio

በOhio ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ 43 ጥናቶች በOhio ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በOhio ውስጥ ያሉ ከተሞች

Official study text (English)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  • Cleveland Clinic Akron General, Akron
  • OhioHealth O'Bleness Hospital, Athens
  • Avon - Richard E Jacobs Health Center, Avon
  • እና 16 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 65 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Summa Health System - Akron Campus, Akron
  • Cleveland Clinic Akron General, Akron
  • Summa Health System - Barberton Campus, Barberton
  • እና 44 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

  • Study Site 104, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT07582432

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
  • Cleveland Clinic Foundation, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
  • እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT04269902

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • GC2202 Study Site 105, Canton
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT05645107

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  • Oncology Hematology Care Clinical Trials, Llc, Cincinnati
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06943872

Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 75 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT07685717

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  • University Hospitals, Cleveland
  • Dayton Physician Network, Dayton
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06846671

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • Dayton Physician Network, Dayton
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06973187

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Oncology Hematology Care Inc, Cincinnati
ተሳታዮችን በመፈለግ ላይደረጃ 4
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07218341

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • University of Cincinnati Medical Center, Cincinnati
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • University of Cincinnati, Cincinnati
  • The Cleveland Clinic Foundation, Cleveland
  • The Ohio State University, Columbus
  • እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT07061951

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

  • Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT07225439

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  • Research Site, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT06564038

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

  • The James Cancer Hospital and Solove Research Institute, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT05091424

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ31 ኦገስ 2026 · NCT07734038

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  • University of Cincinnatti Medical Center, Cincinnatti
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT06528301

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  • OSU Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ኦገስ 2026 · NCT07342478

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • The Ohio State University Wexner Medical Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ ከ13 እስከ 90 · ሁሉም ጾታዎች · የተሻሻለው በ6 ኦገስ 2026 · NCT06533579

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

  • University of Cincinnati, Cincinnati
  • The Ohio State University, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ31 ጁላይ 2026 · NCT06708897

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • University of Cincinnati Medical Center, Cincinnati
  • Cleveland Clinic, Cleveland
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ጁላይ 2026 · NCT05131022

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

  • Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ12 ጁን 2026 · NCT07271667

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

  • Nationwide Children's Hospital, Columbus
  • Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 2 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሜይ 2026 · NCT05418088

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • University of Cincinnati, Cincinnati
  • The Ohio State University, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 13 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT04771572

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • Gabrail Cancer Center Research,, Canton
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ ከ12 እስከ 95 · ሁሉም ጾታዎች · የተሻሻለው በ15 ኤፕሪ 2026 · NCT04329728

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  • Cleveland Clinic Main Campus /ID# 271292, Cleveland
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ኤፕሪ 2026 · NCT06428019

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 4
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ማርች 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  • Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 4
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ማርች 2026 · NCT06876649

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

  • Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ፌብሩ 2026 · NCT06466122

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ፌብሩ 2026 · NCT05336812

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Gabrail Cancer & Research Center, Canton
  • The Ohio State University - The James Cancer Hospital, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ፌብሩ 2026 · NCT05544019

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

  • The Ohio State University /ID# 230439, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ፌብሩ 2026 · NCT04895436

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ጃንዩ 2026 · NCT05417165

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

  • The Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ጃንዩ 2026 · NCT06043674

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

  • University of Cincinnati, Cincinnati
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጃንዩ 2026 · NCT07108998

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

  • University of Cincinnati, Cincinnati
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጃንዩ 2026 · NCT07014917

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ዲሴም 2025 · NCT06757647

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • Taylor Cancer Research Center, Maumee
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ዲሴም 2025 · NCT05602363

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • University Hospitals Cleveland Medical Center, Cleveland
  • The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2025 · NCT05780034

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።